Ligand Pharmaceuticals
LGND
207 hedge funds and large institutions have $2.28B invested in Ligand Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 73 increasing their positions, 71 reducing their positions, and 23 closing their positions.
216% more call options, than puts
Call options by funds: $26.6M | Put options by funds: $8.4M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
10% more capital invested
Capital invested by funds: $2.08B → $2.28B (+$202M)
4.27% more ownership
Funds ownership: 153.4% → 157.68% (+4.3%)
3% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 71
2% less funds holding
Funds holding: 212 → 207 (-5)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$85.2M |
| 2 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$26M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.6M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$16.1M |
| 5 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
+$8.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Conestoga Capital Advisors
Wayne,
Pennsylvania
|
-$57.8M |
| 2 |
Millennium Management
New York
|
-$12.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$6.97M |
| 4 |
RI
Redwood Investments
Boston,
Massachusetts
|
-$6.33M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$5.9M |
LGND Hedge Fund Activity: Q3 2021 in Review
207 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2021, worth a combined $2.28B — up 9.7% from $2.08B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LGND and 18 opened new positions — a net loss of 5 holders — while 71 trimmed existing stakes and 73 added.
The largest buyer was BlackRock, adding an estimated $85.2M. The largest seller was Conestoga Capital Advisors, exiting entirely with an estimated $57.8M sold.
- 207 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2021, down from 212 in Q2 2021.
- Funds reported $2.28B of Ligand Pharmaceuticals stock for Q3 2021, up 9.7% quarter-over-quarter.
- 18 funds opened new Ligand Pharmaceuticals positions in Q3 2021 and 23 closed out, a net change of -5 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2021 was BlackRock, an estimated $85.2M added.
- The largest Ligand Pharmaceuticals seller in Q3 2021 was Conestoga Capital Advisors, an estimated $57.8M sold.
Based on aggregated 13F filings for Q3 2021.